Correlia Biosystems, a Berkeley, CA based life science startup, closed a $7m Series A financing round.
The round was led by Neotribe Ventures, joined by Cota Capital, the Regents of the University of California, and others. NeoTribe Ventures joins Correlia’s board of directors as part of the financing.
The company intends to use the funds for the commercial launch of its immunoassay platform.
This will be the first instrument planned in their larger suite of proteomics tools focused on highly efficient and automated protein measurements.
Led by CEO Akwasi Apori, Correlia is launcing a product to miniaturize Elisa, a quantitative test for proteins and antibodies widely used in drug development, vaccine development and diagnostics. The company combines advances in nanomaterials, automation, and lab-on-a-chip technology to develop a proteomics platform that generates extended data per given sample volume and time. Its platform uses less than one microliter of sample to run rapid, automated assays. This increased performance efficiency opens new opportunities for researchers to expand ELISA based assays in areas where sample volume is a bottleneck, or when fast turn-around times are critical.